Law360, New York (June 26, 2013, 6:32 PM EDT) -- AbbVie Inc. has won a ruling in New York federal court declaring invalid a patent for the anti-inflammatory drug Humira held by the Mathilda and Terence Kennedy Institute of Rheumatology Trust, meaning the drugmaker no longer will have to pay the trust licensing fees.
U.S. District Judge Paul A. Crotty ruled June 20 that the trust's U.S. Patent Number 7,846,442, which covers the cocktail of ingredients that make up Humira, was invalid for obviousness-type double patenting. Judge Crotty presided over the four-day bench trial last fall.
AbbVie, which produces and markets Humira, used to do so under a licensing agreement with...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!
Kirkland & Ellis LLP has redefined what it means to be the biggest of BigLaw — weighing in at 2,116 attorneys by year end 2018 and becoming the first firm since Law360 began tracking law firm head counts to top 2,000 U.S.-based attorneys.